medigraphic.com
ISSN 1561-2988 (Print)

2019, Number 2

<< Back Next >>

Rev Cubana Farm 2019; 52 (2)

Critical analysis of scientific articles on health technologies against respiratory syncytial virus

Jiménez HLG

Language: Spanish
References: 59
Page: 1-27
PDF size: 756.75 Kb.


ABSTRACT

Introduction: Respiratory syncytial virus (RSV) is an infectious agent which generates health problems in vulnerable groups. Health technologies seek to lessen its effects and the economic burden it causes, at the same time as Pharmacoeconomics contributes to clarify the results obtained with its use.
Objective: To make a critical analysis of the scientific articles´ contents on health technologies against respiratory syncytial virus.
Methods: Search and selection of articles in databases with the help of keywords. Analysis of content that allowed detecting the presence in the articles of elements of the methodological design, on the basis of the use of 17 criteria, according to the guide for economic evaluation of health technologies by Lorenzo and others.
Results: 92,5% of the reviewed works were published in English language between 2011 and 2018. Most of the studies came from America and Europe. Of the reviewed aspects, six were not found in some articles, and most difficulties were related to the conflict of interest´s declaration. The economic evaluation with greater representativeness was the cost-effectiveness study.
Conclusions: The scientific article is a reflection of the methodological design that is used in a research on a medicine, and critical analysis of the scientific literature shows that there are various aspects that are needed to be improved on how to present the results related to the use of technologies in health against respiratory syncytial virus.


REFERENCES

  1. García R, Navarro C, Bautista J, Romero A, Beltrán C. Efectividad, seguridad y eficienciadel palivizumab en la prevención de la infección por el virus respiratorio sincitial en prematuros [Internet]. España: Agencia de Evaluaciones Sanitarias de Andalucía; 2014 [acceso 08/11/2018]. Disponible en: https://www.researchgate.net/publication/273074553_ Efectividad_seguridad_y_eficiencia_del_palivizumab_en_la_prevencion_de_la_infeccion_por_el_virus_respiratorio_sincitial_en_prematuros_Effectiveness_safety_and_fficiency_of_palivizumab_for_prevention_r

  2. González J, Ochoa C, Balaguer A. La profilaxis frente al virus respiratorio sincitial conanticuerpos monoclonales (palivizumab) en cardiopatías congénitas: revisión sistemática de eficacia, efectividad y seguridad. Evid Pediatr. 2007 [acceso 02/11/2018];3(23):1-14. Disponible en: https://evidenciasenpediatria.es/files/41-10678-RUTA/La%20profilaxis%20 frente%20al%20virus%20respiratorio%20sinciti.pdf

  3. Palomino M, Prado F, Salinas P, Morgues M, Astudillo P. Estudio de costo efectividad dela profilaxis VSR en Chile. Neumol. pediátr. 2012 [acceso 08/11/2018];185-188. Disponible en: http://www.neumologia-pediatrica.cl/wp-content/uploads/2017/06/EstudioCosto.pdf

  4. United Health Care Oxford. Synagis (Palivizumab) [Internet]. Oxford: Pharmacy UHC;2018 [acceso 08/11/2018] Disponible en: https://www.uhcprovider.com/content/dam/ provider/docs/public/policies/medicaid-comm-plan/synagis-palivizumab-cs.pdf

  5. Gonzales V, Lake J, Martínez E, LaFleur J. Synagis for respiratory syncytial virusprophylasis [Internet]. UTAH, USA: Medicaid Dur Report; 2018. [acceso 08/11/2018] Disponible en: https://medicaid.utah.gov/pharmacy/drugutilization/files/Criteria%20Review %20Documents/2018/2018.04%20Synagis.pdf

  6. Pim K, Huey S. Systematic review of the safety and efficacy of palivizumab amonginfants and young children with cystic fibrosis. Pharmachotherapy. 2017 [acceso 07/11/2018];378(6):755-69. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28423192

  7. López J, Oliva J, Antoñanzas F, García A, Gisbert R, Mar J, Puig J. Propuesta de guíapara la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010 [acceso 07/11/2018];24(2):154-70. Disponible en: http://scielo.isciii.es/scielo.php? script=sci_arttext&pid=S0213-91112010000200012

  8. Banerji A, Ng K, Moraes TJ, Panzov V, Robinson J, Lee BE. Cost-effectiveness ofpalivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic. CMAJ open. 2016 [acceso 08/11/2018];4(4):E623-E633. Disponible en: http://cmajopen.ca/ content/4/4/E623.full

  9. Bentley A, Filipovic I, Gooch K, Busch K. A cost-effectiveness analysis of respiratorysyncytial virus (RSV) prophylaxis in Infants in the United Kingdom. Health econ. rev. 2013 [acceso 03/11/2018];3(1):18. Disponible en: https://www.ncbi.nlm.nih. gov/pubmed/23919494

  10. Blanken M, Frederix G, Nibbelke E, Koffijberg H, Sanders E, Rovers M, Bont L. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr. 2018 [acceso 03/11/2018];177:133-144. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29168012

  11. Carbonell J, de Mercado P. Health economics and RSV. Elsevier Pediatr. Respir. Rev.2009 [acceso 08/11/2018];10(1):12-13. Disponible en: https://www.sciencedirect.com/ science/article/pii/S1526054209700065

  12. Chirico G, Ravasio R, Sbarigia U. Cost utility analysis of palivizumab in Italy: resultsfrom a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high risk preterm infants. Ital. J. Pediatr. 2009 [acceso 10/11/2018];35(4):1-12. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19490659

  13. Choueiry E, Gerbaka B, Hanna N, Fenianos A. Cost effectiveness of palivizumab inprevention against RSV hospitalizations in risk groups. J. Pediatr. Care. 2016 [acceso 01/11/2018];2(3):19. Disponible en: http://pediatrics.imedpub.com/costeffectiveness-of-palivizumab-in-prevention-against-rsv-hospitalizations-in-risk-groups.php?aid=17550

  14. ElHassan N, Sorbero M, Hall C, Stevens T, Dick A. Cost effectiveness analysis ofpalivizumab in premature infants without chronic lung disease. Arch Pediatr. Adolesc. Med. 2006 [acceso 04/11/2018];160:1070-1076. Disponible en: https://www.ncbi.nlm.nih.gov/ pubmed/17018467

  15. Embleton N, Dharmaraj S, Deshpande S. Cost–effectiveness of palivizumab in infancy.Pharmacoeconomics Outcomes Res. 2007 [acceso 02/11/2018];7(5):445-58. Disponible en: https://www.researchgate.net/publication/44654231_Cost-effectiveness_of_palivizumab_ in_infancy

  16. Figueras J, Carbonell X, Quero J. Fernandez B, Guzman J. Echaniz I, Domenecch E.Efectividad de palivizumab en la prevención de la infección por el virus respiratorio sincitial en prematuros de 321 a 350 semanas de gestación en España. Acta Pediatr Esp. 2010 [acceso 02/11/2018];68(1):13-18. Disponible en: http://www.actapediatrica.com/.../122_381370c 553c43a0212b086c25a9e...

  17. Guevara C. Costo utilidad de profilaxis con palivizumab versus no profilaxis en niños deriesgo de infección de virus sincitial respiratorio en Colombia. Rev CES Med. 2014 [acceso 01/11/2018];28(2):203-19. Disponible en: http://revistas.ces.edu.co/index.php/medicina/ article/view/2871

  18. Hampp C, Kauf T, Saidi A. Winterstein, A. Cost-effectiveness of Respiratory SyncytialVirus Prophylaxis in Various Indications. Arch Pediatr. Adolesc. Med. 2011 [acceso 02/11/2018];165:6. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21300647

  19. Hernández Y, Lombardero M, Ortega C, Maciuniak P, Díez A. Cost effectiveness of aprotocol using palivizumab in preterm infants. Farm Hosp. 2017 [acceso 02/11/2018];41(2):169-86. Disponible en: http://scielo.isciii.es/pdf/fh/v41n2/2171-8695-fh-41-02-00169.pdf

  20. Homaira N, Rawlinson W, Snelling T, Jaffe A. Effectiveness of palivizumab inpreventing RSV hospitalization in high risk children: A real world perspective. Int. J. Pediatr. 2014 [acceso 03/11/2018];1-14. Disponible en: https://www.ncbi.nlm.nih.gov/ pubmed/25548575

  21. Kamal S, Doshi J, Campbell J. Economic analyses of Respiratory Syncytial Virusimmunoprophylaxis in high risk infants. Arch Pediatr. Adolesc. Med. [Internet]. 2002 [acceso 02/11/2018];156:1034-1041. Disponible en: https://jamanetwork.com/journals/ jamapediatrics/fullarticle/203934

  22. Lázaro P, Figueras J, Doménech E, Echániz I, Closa R, Wood M, Fitch K. La eficiencia(coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España. An Pediatr. 2006 [acceso 08/11/2018];65(4):316-24. Disponible en: https://www.sciencedirect.com/science/article/ pii/S169540330670203X

  23. Lofland J, Touch S, O´Connor P, Lou M, Moxey E, Paddock L, Nash D, Desai S.Palivizumab for respiratory syncytial virus prophylaxis in high risk infants: A costeffectiveness analysis. Clin. Ther. 2000 [acceso 09/11/2018];22(11):1357-69. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11117660

  24. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab onexpected costs of respiratory syncytial virus infection in preterm infants: Potential for savings. Clin. Ther. 1999 [acceso 02/11/2018];21(1):752-66. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10363740

  25. McGirr A, Schwartz K, Allen U, Solomon M, Sander B. The cost effectiveness ofpalivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model. Hum. Vaccines & Immunotherapeutic. 2017 [acceso 01/11/2018];13(3):599-606. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27768505

  26. McLaurin K, Wade S, Diakun D, Stewart D. Respiratory Syncytial virus hospitalizationoutcomes and costs of full term and preterm infants. J. Perinatol. 2016 [acceso 01/11/2018];36:990-96. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27490190

  27. Meijboom M, Rozembaum M, Benedictus A, Luytjes W, Kneyber M, Wilschut J, HakE, Postma M. Cost effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. Vaccine. 2012 [acceso 03/11/2018];30:4691-4700. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22561315

  28. Neovius K, Buesch K, Sandström K, Neovius M. Cost effectiveness analysis ofpalivizumab as respiratory syncytial virus prophylasis in preterm infants in Sweden. Act. Paediatr. 2011 [acceso 02/11/2018];100:1306-14. Disponible en: https://www.ncbi.nlm. nih.gov/pubmed/21477089

  29. Nuijten M, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis usingobservational data. Eur J Health Econ. 2010 [acceso 03/11/2018];11:105-15. Disponible en: https://link.springer.com/article/10.1007%2Fs10198-009-0206-x

  30. Olchansky N, Hansen RN, Pope E, D’Cruz B, Fergie J, Goldstein M, et al. Palivizumabprophylaxis for Respiratory Syncytial Virus: Examining the evidence around value. Open Forum Infect. Dis. 2018 [acceso 04/11/2018];5(3):ofy031. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833316/

  31. Pouwels K, Bozdemir S, Yegenoglu S, Celebi S, Mcintosh E, Unal S, et al. Potentialcost effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa data. PLoS ONE. 2016 [acceso 02/11/2018];11(9):1-15. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163567

  32. Reeve C, Whitehall J, Buettner P, Norton R, Reeve D, Francis F. Cost effectiveness ofrespiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health. 2006 [acceso 08/11/2018];42:253-58. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16712554

  33. Régnier S. Respiratory syncytial virus immunization program for the United States:Impact of performance determinants of a theoretical vaccine. Vaccine [Internet]. 2013 [acceso 04/112018];31:4347-54. Disponible en: https://www.ncbi.nlm.nih.gov/ pubmed/23896421

  34. Resch B, Gusenleitner W, Nuitjen M, Lebmeier M, Wittenberg W. Cost-Effectiveness ofpalivizumab against Respiratory Syncytial Viral infection in high-risk children in Austria. Clin Ther. 2008 [acceso 08/11/2018];30:749-60. Disponible en: https://www.ncbi.nlm. nih.gov/pubmed/21960187

  35. Rueda J, Rosselli D, Ruiz J. Cost effectiveness of Respiratory Syncytial Virus infectionprophylaxis with palivizumab in preterm infants in Colombia. Coyuntura Económica: Invest. Econ. Soc. 2013 [acceso 07/11/2018];XLIII(21):137-151. Disponible en: https://www.repository.fedesarrollo.org.co/handle/11445/267

  36. Salinas G, Martínez S, Reyes A, Garduño J, Muñoz O, Granados V, Rely K. Costeffectiveness analysis of the use of pavilizumab in the prophylaxis of preterm patients in México. Salud Pública Méx. 2012 [acceso 09/11/2018];54(1):47-59. Disponible en: https://www.repository.fedesarrollo.org.co/handle/11445/267

  37. Sanchez M, Burgos R, Oyagüez I, Aloy F, Sánchez M, Martinón F, Carbonell X. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect. Dis. 2017 [acceso 09/11/2018];17(687):1-11. Disponible en: https://www.ncbi.nlm.nih.gov/ pubmed/29041909

  38. Schmidt R, Majer I, García N, Rivas A, Grubb E, Medrano C. Palivizumab in theprevention of severe respiratory syncytial virus infection in children with congenital heart disease; a /11el cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Econ. Rev. 2017 [acceso 03/11/2018];7(47):1-14. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736509/

  39. Schrand L, Elliot J, Ross M, Bell E, Mutnick A. A cost benefit analysis of RSVprophylaxis in high risk infants. Pharmacoeconomics. 2001 [acceso 02/11/2018];35:1186-93.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11675842

  40. Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W. Assesing variation in the costof palivizumab for Respiratory Syncytial Virus prevention in preterm infants. Pharmacoeconomics Open. 2018 [acceso 02/11/2018];2:53-61. Disponible en: https://link.springer.com/article/10.1007/s41669-017-0042-3

  41. Sharif S, Sharif H, Sharif N, Su Y, Sharif R. RSV infection in Nunavut cost analysis andassociated risk factors: implication of vaccination program and public health planning. Vaccines and Immunol Open Access J. 2018 [acceso 01/11/2018];1(1):26-36. Disponible en: http://ologyjournals.com/vioaj/vioaj_00007.pdf

  42. Lee SR, Kwok KL, Ng DKK, Hon KL. Palivizumab for infants < 29 weeks in HongKong without a clear-cut season for respiratory syncytial virus infection- A cost-effectiveness analysis. J. Trop. Pediatr. 2018 [acceso 05/11/2018];64(5):418-425. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29106671

  43. Tam D, Banerji A, Paes B, Hui C, Tarride J, Lanctôt K. The cost effectiveness ofpavilizumab in term Inuit infants in the Eastern Canadian Arctic. J. Med. Econ. 2009 [acceso 04/11/2018];12(4):361-70. Disponible en: https://www.ncbi.nlm.nih.gov/ pubmed/19900071

  44. Vogel A, McKynlay M, Ashton T, Lennon D, Harding J, Pinnock R, Graham D,Grimwood K, Pattemore P, Schousboe M. Cost effectiveness of pavilizumab in New Zealand J. Paediatr. Child Health. 2002 [acceso 07/11/2018];38:352-57. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12173995

  45. Wegner S, Jacobson J, Liu G, Byrns P, Cypra C, Campbell W, Stiles A. Direct costanalyses of pavilizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatr. 2004 [acceso 09/11/2018];11:1612-19. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15574623

  46. Yekta M, Mutlu B, Kavurt S, Yagmur A, Demirel N, Akyol M Erdeve Ö, Dilmen U.Respiratory syncytial virus prophylaxis in preterm infants: a cost effectiveness study in Turkey. Turk J. Pediatr. 2012 [acceso 06/11/2018];54:344-51. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23692714

  47. Yount L, Mahle T. Economic analysis of Palivizumab PZM in infants with congenitalheart disease. Pediatr. 2004 [acceso 06/11/2018];114:1606-11. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15574622

  48. Rodríguez J, Serrano D, Monleón T, Caro J. Los modelos de simulación de eventosdiscretos en la evaluación económica de tecnologías y productos sanitarios. Gac Sanit. 2008 [acceso 09/11/2018];22(2):151-61. Disponible en: https://www.sciencedirect.com/science/ article/pii/S021391110871224X

  49. Darbá J. La utilización de métodos probabilísticos para la evaluación económica detecnologías sanitarias Gac Sanit. 2006 [acceso 10/11/2018];20(1):74-9. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0213-91112006000100014

  50. Gálvez A, Álvarez M, Sarduy Y, Morales M. Diagnóstico de la evaluación económica ensalud en Cuba. Rev cub salud pública. 2004 [acceso 09/11/2018];30(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S086434662004000100003&lng=es

  51. Ortega A. Farmacoeconomia. Capítulo 2.11 [Internet]. Sf; 2011 [acceso 09/11/2018].Disponible en: https://www.sefh.es/bibliotecavirtual/fhtomo1/cap211.pdf

  52. Simoens S. Assessment of methodological quality of economic evaluations in Belgiandrug reimbursement applications. PLoS One. 2013 [acceso 08/12/2018];8(12):1-8. Disponible en: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0085411 &type=printable

  53. Ma H, Jian W, Xu T, He Y, Rizzo J, Fang H. Quality of pharmacoeconomic research inChina: A systematic review. Medicine. 2016 [acceso 09/12/2018];95(41):1-8. Disponible en: https://journals.lww.com/md-journal/fulltext/2016/10110/Quality_of_pharmacoeconomic_ research_in_China__A.35.aspx

  54. Decimoni TC, Leandro R, Martins Rozman L, Craig D, Iglesias CP, Dutilh Novaes HM,et al. Systematic Review of Health Economic Evaluation Studies Developed in Brazil from 1980 to 2013. Front Public Health. 2018 [acceso 09/12/2018];6(52):1-13. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835950/

  55. Castillo M, Castillo C, Loayza S, Aravena M. Guía metodológica para la evaluacióneconómica de intervenciones en salud [Internet]. Chile: Ministerio de Salud; 2013 [acceso 06/12/2018]. Disponible en: http://www.orasconhu.org/case/sites/default/files/files/EE_ FINAL_web.pdf

  56. Costi M, de Dios J, del Castillo J. Evaluación Económica en Medicina (III). Revisión delas directrices para la realización de evaluaciones económicas. Instrumentos de valoración de la calidad metodológica. Evidencias en pediatría. 2010 [acceso 09/11/2018];6(1):18. Disponible en: https://evidenciasenpediatria.es/files/41-80-RUTA/20Fundamentos.pdf

  57. Gálvez A, Garcia A, Portuondo C, Lara C, Collazo M. Evaluación económica en salud ytoma de decisiones en el contexto sanitario cubano. Rev Cubana Sal Públ. 2012 [acceso 09/112018];38(2):253-62. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext& pid=S0864-34662012000200008

  58. Vallejos C, Bustos L, de La Puente C, Reveco R, Velásquez M, Zaror C. Principalesaspectos metodológicos en la Evaluación de Tecnologías Sanitarias. Rev Med Chile. 2014 [acceso 09/11/2018];142:16-21. Disponible en: https://scielo.conicyt.cl/scielo.php?script= sci_ arttext&pid=S0034-98872014001300003

  59. García A, García J, Gálvez A, Jiménez G. Calidad metodológica de las evaluacioneseconómicas completas, publicadas en revistas médicas cubanas (1999-2014). Rev Cubana Sal Públ. 2016 [acceso 09/11/2018];42(2):183-92. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662016000200002




2020     |     www.medigraphic.com